Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of roxadustat versus epoetin alfa or darbepoetin alfa for maintenance treatment of anemia in dialysis-dependent end-stage renal disease
2013-001497-16Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of roxadustat in anaemia and end-stage kidney disease (ESKD) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Regional primary efficacy endpoints. Started Jul 2014; status: completed.
02
Drugs
roxadustat
03
Conditions
anaemiaend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2013-001497-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001497-16.